Analyst Price Target is $19.25
▲ +414.71% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Atyr PHARMA in the last 3 months. The average price target is $19.25, with a high forecast of $35.00 and a low forecast of $9.00. The average price target represents a 414.71% upside from the last price of $3.74.
Current Consensus is
Buy
The current consensus among 5 contributing investment analysts is to buy stock in Atyr PHARMA.
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Read More